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INTRODUCTION 
The small bowel has been considered for a long time technically difficult to 
evaluate because of its length, location and tortuosity. Since its approval by FDA 
in 2001, capsule endoscopy has revolutionized the study of small bowel and its 
use has been rapidly expanding [1-5]. Several systems have been developed for 
this purpose. One of the main limitations to its diffusion has been the relatively 
high cost and thus a questionable cost-effectiveness ratio. More recently, a new 
videocapsule system (OMOM CE) has been developed in China by Jinshan 
Science & Technology Company (Chongqing, China) [6,7] and has obtained the 
CE mark for its marketing in Europe. Its cost is approximately half that of other 
capsule systems. However, there are few studies addressing the clinical 
experience with this new videocapsule system and none of them has been 
performed in the western world. 
Aim of the present study was thus to assess the feasibility, safety and diagnostic 
yield of the OMOM CE in different clinical settings related to possible small 
bowel disease conditions. 
 
 
CapsoCam SV1 is a newly introduced device for small-bowel (SB) capsule 
endoscopy (CE) with wire-free technology, a long-lasting battery life, and 12–20 
frames per second captured by four high-resolution cameras located on the 
capsule sides and facing the four quadrants of the digestive wall. Initial 
experiences have shown high operative performances, suggesting at least an 
equal clinical efficacy compared to other frontal view capsules. 
 
Furthermore, in the last year, we conducted a multicenter, observational, 
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spontaneous study to assess the performance of CapsoCam SV1 in real life 
clinical practice. 
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 PATIENTS AND METHODS 
 
Patients 
A total of 118 patients (61 men, 57 women, mean age 53 years, range 18-86) 
with suspected small bowel disease underwent OMOM CE in 3 
Gastroenterology Units (Gastroenterology & Digestive Endoscopy Unit, IRCCS 
Policlinico San Donato - University of Milan; Surgery & Digestive Endoscopy 
Unit, V. Monaldi Hospital, Naples; Santa Barbara Hospital, Iglesias). 
Indications to the exam consisted of the following: obscure gastrointestinal 
bleeding, known or suspected Crohn’s disease, suspected small bowel tumor, 
familial adenomatous polyposis. The numbers of patients studied for each 
diagnostic subgroup are reported in table 1. All patients had previously 
undergone upper and lower gastrointestinal endoscopy. Most of them had also 
undergone other investigations, such as small bowel follow through, 
enteroclysis, abdominal computed tomography and magnetic resonance.  
In the second part of the study, 50 patients with suspected small bowel disease 
underwent OMOM CE in 4 Gastroenterology Units. 
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Methods 
The OMOM capsule endoscopy (Jinshan Science & Technology Company, 
Chongqing, China) was used in all patients. This system is made up of three 
parts: a disposable capsule, an image recorder jacket and an image workstation. 
The capsule measures 12.5x27.5 mm and weighs < 6 gr. Image features include 
a 150° field of view and a resolution of 0.1 mm. The capsule has a battery life of 
approximately 7-9 hours. The pictures are generally taken at a rate of two frames 
per second, but the rate can be adjusted to needs during the exam, a unique 
feature of this system. There are 14 receiver elements placed close to the 
abdomen and to the waist in the recorder jacket. The capsule transmits the 
acquired images via a digital radio frequency communication channel to the 
recorder. A portable real-time monitor device allows the endoscopist to follow 
the progression of the capsule and to send possible commands to the OMOM 
system: in order to modify rate of frame (2 frames per second, 1 fps or 0.5 fps), 
flash intensity, conditions of capsule (sleep or awake). 
The recorder is later connected to the workstation, in which the images are 
downloaded and processed.  
The main differences between the OMOM capsule endoscopy and the other 
currently available systems of capsule endoscopy are a slightly bigger size and 
the use of an antenna-carrying jacket by the OMOM system. Also, further 
features of the OMOM system are the possibility of modulating frame recording 
speed and a significantly lower cost. The main features of the system are shown 
in figures 1-3.  
All subjects followed a clear semi-liquid diet on the day before and  2L of PEG 
(polyethylene glycol solution) in the afternoon before the procedure. 
In one of the three center the real time monitor was used to check the passage 
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out of the stomach into the small bowel. If the capsule had not passed  the 
pylorus after 60 minutes, metoclopramide 10 mg was administered 
intravenously. 
The acquired images were reviewed by two expert gastroenterologists and all 
videos were classified as: diagnostic, suspicious or negative.  
 
In the second part of the study, patients with suspected SB disorders were 
consecutively enrolled in 3 Italian centers during 2014 and underwent to 
CapsoCam SV1 capsule examination. Two expert readers performed a 
centralized post-hoc revision of those video recordings with undefined findings. 
The P0/P1/P2 classification proposed by Saurin et al. [50] for obscure gastro-
intestinal bleeding (OGIB) was used to assess the clinical relevance of all 
findings.  
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Study Flow Diagram 
 
 
 
 
 
 
 
Statistical analysis  
Quantitative variables were expressed as mean ± SD values. Fisher’s test was 
used to compare occult OGIB and overt OGIB diagnostic yield. 
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 RESULTS  
All patients ingested the OMOM capsule very easily and no complications were 
observed. 
All data analyzed were normally distributed. The recording time was 420 to 580 
minutes (mean time 514 min, SD 39). Surprisingly, the mean pyloric transit time 
-defined as the recorded time of the first image of duodenum- was 78 minutes 
(SD 44) in patients who received metoclopramide and 27 minutes (SD 16) in 
those who did not receive metoclopramide.  
The mean small bowel transit time –defined as the time from the first duodenal 
image to the time of the first cecal image for patients in whom the capsule 
reached the cecum - was 241 minutes (SD 123) in patients who received 
metoclopramide and 235 minutes (SD 73) in those who did not receive 
metoclopramide. Patients in whom the capsule did not reach the cecum were 
excluded from analysis of small bowel transit time. 
 
Visualization of the entire small bowel was achieved in 114 patients (97%) and 
capsule retention without obstruction occurred in 1 patient (0.8%) due to a 
previously undiagnosed Crohn’s disease stricture at the terminal ileum in a 
patient with diarrhea but without obstructive symptoms. This patient underwent 
surgical treatment of the stricture and capsule recovery. 
In 4 patients the capsule did not reach the cecum within the time of recording. In 
3 of them the capsule failed to reach the cecum because of the impact with a 
lesion (a jejunal stricture due to a previously unknown Crohn’s disease in one 
patient, an ileal mass in one patient and a duodenal substenosis in the last one), 
and in 1 patient the only finding was angiodysplasia. In all cases, capsule was 
spontaneously expelled in 10 days in all patients except in 1 patient who 
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experienced a retention symptomless and underwent surgical treatment of a 
previously undiagnosed Crohn’s disease stricture and capsule recovery.  
 
When only positive findings are considered, the overall diagnostic yield was 
48%. When also suspicious findings are considered, diagnostic yield increases 
up to 58%.  Diagnostic yield observed in the different subgroups are reported in 
table 2.  
Diagnostic yield in patients with OGIB was 76% (when positive and suspicious 
findings are considered). It was greater than the yield in the non-OGIB 
subgroup, confirming that OGIB is the most important indication for capsule 
endoscopy. When patients were divided according to the type of bleeding (overt 
vs. occult), the diagnostic yield in OGIB was similar (p=0,7) as shown in table 3. 
 
Angiodysplasia was the most common finding  [8] and all these type of lesion 
were observed in the OGIB subgroup. Other findings included ulcers, erosions, 
polyps, active bleeding with no recognizable lesion, small-bowel tumors. All the 
findings are reported in table 4. The main findings are shown in figures 4-7.  
 
Regarding the second part of the study on CapsoCam capsule system, fifty 
patients underwent SBCE (26 men; median age 67±17 years, range 16-86 years) 
with the following indications: 35 OGIB (27 occult), 8 iron-deficiency anemia, 
and 7 suspected Crohn’s disease. No procedure’s failure occurred.  
The small bowel completion rate was 96%, the mean mucosal visibility and the 
video image quality were always scored as optimal. The Vater’s ampulla was 
identified in 52% with a mean of 2.5 frames for each positive case. 
One prolonged SB transit time in a young man with severe and diffuse 
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ulcerative-enteritis according to he further diagnosis of Crohn’s disease.  
 To perform the “per lesion” analysis of results, we excluded 125 SB lesions (28 
P1, 97 P2) observed in a single woman with a pan-enteric Crohn’s disease; 201 
findings were detected in the remaining recordings (26 P0, 81 P1, 94 P2). Most 
lesions were in the SB (168) and showed relevant clinical potential (14 P0, 63 
P1, 91 P2 lesions). Interestingly, thirty lesions were detected in the upper-GI (11 
P0, 9 P1, 10 P2). On a per patient analysis, 78% subjects had one or more 
findings (median=3) with a diagnostic yield of 70% (22% P1 and 48% P2 
lesions). 
3 patients (2 IDA, 1 OGIB-overt) underwent frontal-viewing SBCE with 
negative result. These patients underwent to a second look with Capsocam; in 2 
patients we found P1 lesions, in 1 patient a P2 lesion (non-bleeding 
angiodisplasia). 
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DISCUSSION 
Since the development of the first model of capsule endoscopy, continuing 
technological progress has further led to important technical advancement and 
thus capsule endoscopy has become a very important tool for the evaluation of 
suspected or known small bowel disease conditions.  
However, in times of strict cost containment, the high cost of this procedure has 
represented the main limitation of its use. A relatively low-cost capsule 
endoscopy was recently developed and used in large patients populations in 
China. This is the first study to evaluate the overall performance of OMOM 
capsule endoscopy in a group of patients of caucasian origin. 
In our hands, the system was easy to use and safe. Retention without obstruction 
occurred in 1 patient due to a previously undiagnosed Crohn’s disease stricture at 
the terminal ileum. Also in this case, however, retention was symptomless; the 
patient underwent surgical treatment of the stricture and capsule recovery. 
Some features of the system also appear to be very useful in making the 
procedure more adjustable and tailored to specific clinical needs. In particular, 
the possibility of modulating flash intensity and the ON/OFF status of the 
capsule are unique of this system. While the first one might be useful in 
condition of low visibility (stomach, residues or bleed in the lumen), the second 
one may be helpful in saving battery life when a distal lesion has to be reached. 
Another important feature is the possibility of monitoring the pyloric transit in 
order to decide whether or not to use a prokinetic to fasten it up; in fact, it is 
known that a delayed gastric time is one of the most frequent causes of failure to 
reach the cecum [9,10]. 
In our series, OMOM capsule endoscopy reached the cecum in a very high 
proportion of patients (97%). This is a much higher figure than that usually 
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reported in the literature for all other capsule systems [11-13]. Although 
prokinetics may be useful in obtaining this result [10,14], this does not appear to 
be the case in our study. In fact, when we analyze patients for centers not 
utilizing either prokinetics injection or real-time viewer, an even higher  
proportion of reachment of cecum (37/38 patients, 97%) was observed, thus 
ruling out the possible role of these factors. 
The OMOM capsule endoscopy is slightly bigger and heavier than other 
capsules and this might favor a relatively faster progression along the small 
bowel. Also, our patient series is characterized by a relatively large proportion of 
patients with clinical conditions, such as diarrhea and overt OGIB, possibly 
leading to accelerated peristalsis and a short small bowel transit time. Indeed, the 
small bowel transit time observed in the present study is quite short but 
substantially similar to those observed in the literature. 
This might be explained considering that transit speed could be affected by 
multiple variables: completion rate, different definitions of the small bowel 
transit time used in the literature (many Authors have included patients in whom 
capsule enteroscopy has never reached the cecum), age of patients, comorbidities 
and drugs affecting bowel peristalsis (such as diabetes and neuropathies or 
opiods and prokinetics respectively), in-patients or out-patient, etc. Another 
possible explanation for this result is the relatively longer lifespan of OMOM 
capsule endoscopy batteries, allowing a longer duration of recording.  
In any case, a more complete visualization of the small bowel could be of 
importance in obtaining even a higher diagnostic yield than that obtained by 
current devices.  
In our series the diagnostic yield was assessed considering positive findings only 
(see table 2) and results are similar to those reported in literature with an overall 
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detection rate of 48%. More in details, it was 60% in OGIB and 35% in known 
or suspected Crohn’s disease. Consistently, as previously described in the 
literature, the diagnostic yield is rather variable according to the different 
indications for capsule endoscopy: about 50% for OGIB in a recent series 
[11,15-16], widely ranging between 33-70% for suspected Crohn’s disease [16-
18].  
The results of the present study are quite encouraging showing diagnostic figures 
at least similar to those reported in the literature, although the relatively small 
number of patients evaluated makes a statistical comparison unfeasible. 
In conclusion, OMOM capsule endoscopy appears to be a practical, safe, easy to 
perform procedure, providing a similar diagnostic yield and an even superior 
time of observation of the small bowel.  
Its significantly lower cost compared to all other systems marketed in Europe 
should also encourage its diffusion because of a better cost/effectiveness ratio. 
 
The recently introduced CapsoCam SV1 appears to be a very dependable and 
effective system in the study of patients with SB disorders. In our series, 
preliminary results showed a high diagnostic yield of this new device and 
suggested an alternative not only use but also complementary to the capsules in 
frontal view, in order to further increase the diagnostic value of the survey 
capsular. 
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Figure 8. 
 
 
 
  CapsoCam SV1 
 
 
 
 
 
Field of View: 
Frame Rate: 
Battery Life: 
Data Storage: 
Transmission: 
Size/weight:  
360°panoramic view 
12/20 frames per second 
15 hours 
On-board EPROM Flash Memory 
USB 
11 mm x 31 mm / 4gr 
 
Figure 1:  CaspoCam SV1 
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Figures 9-10. 
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Figure 2:  multiple ulcers of distal jejunum, later diagnosed as CD 
Figure 4:  edema, hyperemia and lymphangectasia of proximal jejunum 
Figure 3:  diffuse gastopathy related to portal hypertension  
Figure 5:  ulcerative enteritis of the ileum, later diagnosed as ishemic  
Figure 6:  aphtous ulcers of the proximal jejunum Figure 7:  fresh blood and aphtous ulcers in the proximal ileum 
Figure 8:  nonbleeding angectasia (2-3mm) of the medium jejunum Figure 9:  hyperemic duodenitis with one aphtous ulcer 
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Pan-enteric Crohn’s disease 
 
5-6mm-large, not-bleeding typical angectasia 
 
 
 
 
Table 1. Indications for capsule endoscopy 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2. Diagnostic yield  
 
 
 Indications of patients for capsule 
endoscopy 
 Number 
Obscure gastrointestinal bleeding 55 
Known or suspected Crohn’s disease 57 
Familial adenomatous polyposis 3 
Suspected small bowel tumor  3 
Total patients 118 
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Indication Nr Positive Suspicious Negative 
Obscure GI bleeding 55 33 (60%) 9 (16%) 13 (24%) 
Suspected or known 
Crohn’s disease 
57 
20 (35%) 3 (5%) 34 (60%) 
FAP 3 1 (33%) 0 (0%) 2 (67%) 
Suspected small 
bowel tumor 
3 
2 (67%) 0 (0%) 1 (33%) 
Total 118 56 (48%) 12 (10%) 50 (42%) 
 
 
Table 3. Diagnostic yield in OGIB 
 
 
Indication Nr Positive Suspicious Negative 
OGIB Occult 34 20 (59%) 6 (18%) 8 (23%) 
OGIB Overt  21 14 (67%) 1 (5%) 6 (28%) 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4. Small-bowel finding in positive patients 
 
 
Findings Overall OGIB Non OGIB 
MAV  15  15  0  
Ulcer  20 14 6 
Erosions 6 2 5 
Polyps  4 3 1 
Active bleeding 6 6 0 
Stricture 3 1 1 
Villous atrophy  2 0 1 
Tumor 2 0 1 
1 patient had two type of lesion. 
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